<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004753</url>
  </required_header>
  <id_info>
    <org_study_id>199/11677</org_study_id>
    <secondary_id>UCLA-90063784</secondary_id>
    <nct_id>NCT00004753</nct_id>
  </id_info>
  <brief_title>Long-Term Study of Cerebral Glucose Metabolism in Huntington's Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Correlate clinical outcome with cerebral glucose metabolism in patients with&#xD;
      Huntington's disease (HD) and their at-risk relatives.&#xD;
&#xD;
      II. Evaluate the efficacy of cerebral glucose metabolism in observing the pathophysiologic&#xD;
      development of HD, monitoring responses to experimental therapy, and predicting HD genotype.&#xD;
&#xD;
      III. Identify, define, and describe the natural history of pathophysiologic lesions in HD.&#xD;
&#xD;
      IV. Characterize the genotypic and phenotypic expression of the HD gene.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: Participants are screened for Huntington's disease, including cerebral&#xD;
      glucose metabolism assessment and genetic testing.&#xD;
&#xD;
      Studies include a detailed family history and neurologic, psychometric, and neurobehavioral&#xD;
      evaluations. Imaging includes positron emission tomography with fluorodeoxyglucose and brain&#xD;
      magnetic resonance imaging.&#xD;
&#xD;
      A genotype assessment is performed; genetic results are not disclosed to patients or&#xD;
      relatives.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1993</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <enrollment>90</enrollment>
  <condition>Huntington's Disease</condition>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
          -  Documented family history of Huntington's disease (HD)&#xD;
&#xD;
          -  Symptomatic HD: chorea required&#xD;
&#xD;
          -  At-risk for HD: no detectable systemic or oculomotor abnormality&#xD;
&#xD;
          -  Age-matched control subjects&#xD;
&#xD;
          -  No history of inherited neurological disease&#xD;
&#xD;
          -  No general or neurologic abnormality&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
        At least 4 weeks since other HD treatment, e.g.:&#xD;
&#xD;
          -  Haloperidol&#xD;
&#xD;
          -  Benzodiazepine&#xD;
&#xD;
          -  Other tranquilizers or neuroleptics&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
          -  No pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>0 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John C. Mazziotta</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <verification_date>December 2001</verification_date>
  <study_first_submitted>February 24, 2000</study_first_submitted>
  <study_first_submitted_qc>February 24, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2000</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Huntington's disease</keyword>
  <keyword>neurologic and psychiatric disorders</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

